
13.00 Delayed Data As of May 27 | ![]() Today’s Change | 9.26 Today|||52-Week Range 24.00 | -10.59% Year-to-Date |
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade May 27 / Zacks.com - Paid Partner Content | Philips' (PHG) Launches a Range of New Products at EuroPCR 2022 May 17 / Zacks.com - Paid Partner Content |
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M May 17 / Zacks.com - Paid Partner Content |
Previous close | 12.47 |
Today’s open | 12.57 |
Day’s range | 12.12 - 13.20 |
Volume | 337,318 |
Average volume (3 months) | 475,076 |
Market cap | $806.3M |
Earnings growth (last year) | -33.56% |
Earnings growth (this year) | +4.79% |
Earnings growth (next 5 years) | +38.60% |
Revenue growth (last year) | +4.30% |
P/E ratio | -- |
Price/Sales | 122.00 |
Price/Book | 3.76 |
---- | ||
CRNXCrinetics Pharmaceut... | -0.33 | -1.93% |
KURAKura Oncology Inc | +0.96 | +7.65% |
ENTAEnanta Pharmaceutica... | +1.34 | +3.51% |
Next reporting date | August 11, 2022 |
EPS forecast (this quarter) | -$0.36 |
Annual revenue (last year) | $6.8M |
Annual profit (last year) | -$90.9M |
Net profit margin | -1,343.96% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Wayne, Pennsylvania |